NUVB
The table below shows Nuvation Bio Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $62.90M | $7.87M | $0.00 | - | - | - |
| Cost of revenue | - | $7.08M | $0.00 | - | - | - |
| Gross profit | - | $795.00K | $0.00 | - | - | - |
| R&D | $115.11M | $99.12M | $71.29M | $87.81M | $69.04M | $32.60M |
| SG&A |
Nuvation Bio Inc. reported annual revenue of $62.90M for fiscal year 2025. That is up 699.0% from $7.87M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $151.56M |
| $69.23M |
| $28.53M |
| $31.92M |
| $24.28M |
| $10.95M |
| Operating income | -$213.06M | -$592.63M | -$99.82M | -$119.73M | -$93.32M | -$43.55M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$204.63M | -$567.94M | -$75.80M | -$104.20M | -$86.85M | -$41.66M |
| EPS (diluted) | -$0.60 | -$2.11 | -$0.35 | -$0.48 | -$0.44 | - |